Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus
NCT07205900Phase 2Active, not recruiting
- Sponsor
- Hanmi Pharmaceutical
- Start
- Dec 2025
- Primary completion
- Jan 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of efocipegtrutide in obesity, sponsored by Hanmi Pharmaceutical. Started Dec 2025; status: active, not recruiting.
02
Drugs
efocipegtrutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07205900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07205900.